Important Notes:
In January 2021, BEBIG Medical GmbH took over the global production and distribution structures of the HDR brachytherapy products of Eckert & Ziegler BEBIG GmbH including Mick Radio-Nuclear Instruments, Inc.
Below news are related to the HDR brachytherapy business and is quoted originally from the website:
Original Content:
CE approval has been recieved for the world's first applicators manufactured by 3D printing and designed for the treatment of gynecological tumors. Made of biocompatible and sterile plastic, the attachments extend the range of applications of conventional applicators. They are now also suitable for targeted, needle-assisted brachytherapy using HDR afterloading and can significantly increase the 3-year survival rate of cancer patients.
"Thanks to the new applicator add-on kits, we can now offer patients with advanced cervical cancer an optimal therapy that can be used to treat tumors with complex volumes that are difficult to properly cover. At the same time, it facilitates our work process, as the applicator is already delivered sterile. In order to be able to treat the patient-specific findings even better, the add-on kits are available in fifteen different forms," explained Professor Dr. Jean-Michel Hannoun-Levi, Head of the Radiotherapy Department at the Centre Antoine Lacassagne in Nice.
"The CE mark is an important milestone for us, as the add-on kits are the world's first 3D printed medical product family approved for needle-assisted brachytherapy", said Dr. Harald Hasselmann, member of the Executive Board of Eckert & Ziegler AG. "The 3D printing process, which has been specially developed and validated for the manufacture of sterile medical products, opens up completely new possibilities for the further development of our product portfolio and thus for the treatment of many types of cancer".
The add-on kits fit to nearly all common HDR treatment devices and thus can be used in many clinics.
HDR (high dose rate) brachytherapy is conducted with a so-called HDR afterloader, also known as a remote afterloading system. With the help of applicators and catheters, the very small radiation source is driven from a shielded safe – located inside the afterloader – directly into or next to the tumor. A computerized treatment planning program calculates precisely how long the source has to stay and radiate at the so-called dwell positions before being driven back into the safe. HDR brachytherapy can often be performed on an out-patient basis. It is conducted in only a few treatment sessions, destroys the tumor cells and spares surrounding healthy tissue as the radiation is applied from within the tumor. This noticeably increases the patient’s quality of life.
About BEBIG Medical GmbH:
BEBIG Medical GmbH (“BEBIG Medical”) is a global provider of high quality radiation therapy products for cancer treatment headquartered in Berlin, Germany. Preceded by the high dose brachytherapy business unit of Eckert & Ziegler AG, BEBIG Medical has a heritage of more than 40 years’ experience in brachytherapy field and continues to provide affordable healthcare with proven clinical outcomes via strong and viable technology.BEBIG Medical’s US subsidiary, Mick Radio-Nuclear Instruments, Inc., is also known internationally for its manufacturing expertise in the field of applicators and accessories to advance brachytherapy. With a team of professionals and offices in Europe, United States and Asia, the company is empowered to serve customers in more than 65 countries and regions together with a worldwide distribution network.
Contact:
Crystal Chen, Chief Commercial Officer: crystal.chen@bebigmedical.com
Home
